Identification of serum biomarkers for diagnosing stage I lung adenocarcinoma by MALDI-TOF mass spectrometry
- Author:
Xin-Ju LI
1
Author Information
1. Department of Thoracic Surgery
- Publication Type:Journal Article
- Keywords:
Adenocarcinoma;
Biomarker;
Lung neoplasm;
Matrix-assisted laser desorption ionization time of flight mass spectrometry (MALDI-TOF-MS);
Proteomics
- From:Academic Journal of Xi'an Jiaotong University
2009;21(2):134-137
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To identify specific biomarkers that could improve early diagnosis of lung adenocarcinoma using matrix-assisted laser desorption/ionization (MALDI) technology. Methods: Serum samples were isolated from 17 patients with stage I lung adenocarcinoma and 17 age- and sex-matched healthy controls, and the serum proteomic profiles were obtained by matrix-assisted laser desorption ionization time of flight (MALDI-TOF) mass spectrometry. Results: Compared with healthy control group, two highly expressed potential biomarkers were identified with the relative molecular weights of 6631.64 Da and 4964.21 Da. The two best novel protein peaks were automatically chosen for the system training and the development of the constructed model. The constructed model was then used to test an independent set of masked serum samples from 15 lung adenocarcinoma patients and 22 healthy individuals. The analysis yielded a sensitivity of 93.3%, and a specificity of 95.5%. Conclusion: These results suggest that MALDI-TOF-MS ProteinChip technology is a quick, convenient, and high-output analyzing method that is capable of selecting several relatively potential biomarkers from the serum of lung adenocarcinoma patients and may have a clinical value in the future, and will provide clues to identifying new serologic biomarkers of lung adenocarcinoma.
